Valeant Pharmaceuticals International subsidiary Bausch + Lomb has obtained 510(k) approval for Swept Source Optical Coherence Tomography (OCT) imaging system and updated software for its Victus Femtosecond Laser Platform.
According to the company, the new software and imaging system will deliver auto-recognition of key landmarks in the eye, including the pupil, anterior capsule and posterior capsule, along with the capsule tilt compensation to maximize lens fragmentation.
The Swept Source OCT provides high resolution imaging and can be used to drive incision depth and detail the architecture of arcuate incisions.
Other features of the advanced Swept Source OCT and software include improved imaging speed and sensitivity compared to conventional time domain detection techniques with responsive video frame rate.
Valeant Pharmaceuticals International executive vice-president and company group chairman Dr Ari Kellen said: "With the availability of the advanced OCT imaging and software enhancements, surgeons can monitor treatments in real-time and with exceptional clarity throughout entire procedures, providing even greater control and consistency to support outstanding surgical outcomes for their patients.
"These new advancements demonstrate Valeant’s commitment to innovation in eye health. We want to deliver technologies that improve clinical practice and provide the best quality of vision to patients."